Furmonertinib side effects usually begin to appear within a few days and analysis of symptoms

Furmonertinib (Furmonertinib) is an oral third-generation EGFR tyrosine kinase inhibitor, mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC). It targets the EGFR T790M mutation and effectively inhibits tumor cell proliferation and signal transduction. Similar to other EGFR inhibitors, fumetinib may cause certain side effects during treatment, usually manifesting as systemic reactions such as skin, gastrointestinal tract, and hematology.

Clinical observations show that most of the side effects of fumetinib begin to appear within 1 to 4 weeks after taking the drug. Some symptoms may have cumulative effects after several days of continuous use. For example, rashes and dry skin usually appear at the end of the first week of taking the drug, while hematological abnormalities, such as a decrease in white blood cells or platelets, are often detected within 2–4 weeks. Early identification of side effects is critical for timely intervention and maintenance of treatment continuity.

Common side effects of fumetinib include skin reactions (rash, itching, dryness), gastrointestinal symptoms (nausea, diarrhea, loss of appetite), liver function abnormalities (ALT, AST increases), and mild to moderate hematological changes (mild decreases in white blood cells and platelets). A small number of patients may develop interstitial lung disease (ILD) or QT interval prolongation, requiring close monitoring of cardiopulmonary function. The severity of side effects varies between individuals, and most are mild to moderate and can be alleviated by symptomatic treatment or brief discontinuation of medication.

In order to reduce the impact of side effects on treatment, patients should pay close attention to changes in skin, digestive system and blood indicators in the early stages of medication. Topical emollient or antihistamine drugs can be used when rash or itching occurs; gastrointestinal discomfort can be treated with small frequent meals, oral antidiarrheal or anti-nausea drugs; abnormal liver function or severe hematological changes require dose adjustment or suspension of medication. Regular follow-up and early intervention can ensure that the efficacy of fumetinib is maximized, while reducing the risk of side effects and maintaining patient treatment tolerance and quality of life.

Reference materials:https://www.drugs.com/